Incyte Corp (INCY) Price

Incyte Gains 40% YTD, Sets Stage for J.P. Morgan Conference

Incyte will present at the J.P. Morgan Healthcare Conference on January 12, 2026, as its stock has outperformed the market with a greater than 40% year-to-date gain.

Incyte Wins EU Approval for Minjuvi After Trial Shows 57% Reduction in Lymphoma Progression Risk

Incyte's follicular lymphoma drug, Minjuvi, gained European Commission approval after a Phase 3 trial showed it extended median progression-free survival to 22.4 months from 13.9 months.

Lumentum Bolsters Board with Thad Trent Appointment

Lumentum has appointed Thad Trent to its Board of Directors, increasing its size to nine members. This move comes amid a broader trend of leadership changes across various sectors, signaling a strategic focus on governance and experience with minimal immediate market reaction.

Hercules Pharma Taps New CCO to Drive Growth

Hercules Pharmaceuticals appointed Ali Ahmed as Chief Commercial Officer to spearhead its commercial strategy and growth. The move is viewed as a strategic effort to bolster its market position, reflecting a broader trend of leadership changes across sectors aimed at driving commercial performance.

Incyte Board Changes Amid Sector-Wide Leadership Volatility

Hervé Hoppenot, Incyte's former Chairman and CEO, has resigned from the Board of Directors. The departure, though part of a planned transition, occurs as the broader biopharma industry grapples with significant executive turnover and profound regulatory uncertainty at the FDA.

Healthcare Stocks Gain on White House Proposal to Extend ACA Subsidies

Incyte Stock Surges Over 46% Year-to-Date, Analysts Cite Undervaluation Metrics